THJ-2201

THJ-2201 is a synthetic cannabinoid in the indazole-carboxamide family and the 5-fluoropentyl analogue of THJ-018. It was identified in forensic monitoring in 2014 and became associated with a substantial number of laboratory reports and adverse-event concerns. Human hepatocyte studies have shown extensive metabolism, including oxidative defluorination, while clinical reports describe serious synthetic cannabinoid intoxications in which THJ-2201 was sometimes detected with other substances.

Chemistry and identification

THJ-2201 is (1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone. It retains the indazole-naphthoyl structure of THJ-018 but carries a fluorine atom at the terminal carbon of the N-pentyl chain. It is structurally related to AM-2201, which is the corresponding fluorinated indole rather than indazole compound.

The National Forensic Laboratory Information System recorded 220 reports of THJ-2201 by the time of a 2016 metabolism paper. The DEA placed it in Schedule I in January 2015 following reports of adverse events (Diao and colleagues, 2016).

Pharmacology

THJ-2201 is classified as a synthetic cannabinoid receptor agonist. Its structure suggests activity at CB₁ receptors, but the most detailed compound-specific research has focused on metabolism and forensic detection. The terminal fluorine changes the metabolic pathways compared with THJ-018 and should not be treated as a chemically insignificant substitution.

Metabolism

In human hepatocytes, researchers identified 27 THJ-2201 metabolites. The dominant pathways involved oxidative defluorination, followed by carboxylation or glucuronidation, as well as glucuronidation of hydroxylated metabolites. Dihydrodiol formation on the naphthalene ring was also observed. The results show why metabolite-based testing is important when investigating exposure (Diao and colleagues, 2016).

Oxidative defluorination produces metabolites that can resemble those formed from non-fluorinated analogues. This can complicate interpretation if laboratories rely on a narrow set of screening targets.

Reported effects and clinical findings

THJ-2201 was reported in forensic and clinical monitoring during a period when several new synthetic cannabinoids were appearing in herbal products. The 2016 metabolism paper notes numerous adverse events associated with the compound, but includes no controlled assessment of human effects. Clinical reports involving synthetic cannabinoid mixtures often include agitation, confusion, seizures and cardiovascular disturbances; co-exposures make compound-specific attribution difficult.

Toxicity and research limitations

There is no controlled human study establishing the acute toxic range, dependence potential or long-term effects of THJ-2201. Its forensic history and international control status reflect public-health concern, but the available clinical record does not support a precise concentration-toxicity relationship.

THJ-2201 is not interchangeable with THJ-018 or AM-2201. It has an indazole core and a fluorinated pentyl chain, and its metabolism differs from both related compounds.

Related compounds

THJ-2201 is related to THJ-018, AM-2201 and JWH-018. It is the 5-fluoropentyl analogue of THJ-018.